TENX

Tenax Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website enaxthera.com
Employees(FY) 7
ISIN US88032L6056

Performance

-9.36%

-9.77%

+37.44%

+73.82%

-4.52%

YTD

-54.84%

Profile

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Advanced Technical Analysis

Technical Analysis of TENX 2025-01-31

The stock indicators reflect a neutral sentiment, with the Moving Average Score at 50, Oscillators Score at 56, and a Technical Score of 55, suggesting a balanced market condition without strong bullish or bearish signals. Overall, these scores indicate that while there is some upward momentum, the market remains cautious and indecisive.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TENX

Stock Rank

Recent News & Updates

2025-01-30 20:00
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference(Globenewswire)
2025-01-21 19:00
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations(Globenewswire)
2024-11-12 18:19
Tenax Therapeutics: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-12 18:00
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update(Globenewswire)
2024-11-03 18:30
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors(Prnewswire)
2024-10-31 04:05
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference(Globenewswire)
2024-08-13 04:37
Tenax Therapeutics: Q2 Earnings Snapshot(Yahoo Finance)
2024-08-13 04:05
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update(Globenewswire)
2024-08-11 20:00
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program(Globenewswire)
2024-08-05 19:13
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement(Globenewswire)
2024-05-14 01:53
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-13 20:10
Tenax Therapeutics: Q1 Earnings Snapshot(Yahoo Finance)
2024-05-13 20:00
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update(Globenewswire)
2024-04-29 19:30
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Globenewswire)
2024-04-08 20:30
Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study(Globenewswire)
2024-03-28 09:54
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-27 20:30
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results(Globenewswire)
2024-03-11 20:30
Tenax Therapeutics to Present at the 36th Annual Roth Conference(Globenewswire)
2024-02-28 20:00
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024(Globenewswire)
2024-02-19 19:30
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan(Globenewswire)
2024-02-07 19:53
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?(Investorplace)
2024-02-07 19:16
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering(Globenewswire)
2024-02-07 07:01
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Globenewswire)
2024-02-05 19:30
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)(Globenewswire)
2023-12-28 19:30
Tenax Therapeutics Announces Reverse Stock Split(Globenewswire)
2023-11-16 19:30
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board(Globenewswire)
2023-11-13 16:05
Tenax Therapeutics: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-13 02:22
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?(Investorplace)
2023-11-12 19:30
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023(Globenewswire)
2023-08-27 20:20
TENX: Second Quarter Results(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.